OakChart

Immunic Inc

IMUXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 1:38 PM ET

8.16+0.12 (1.49%)
2026-11-11 19:39 CET
Market cap
109.70 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-111.57 USD m
Free cash flow, TTM
-88.05 USD m
EPS diluted, TTM
-4.81
P/E
-
Compare

Price

IMUX against its 20, 50 and 200-day averages
2050200beatmiss
7.5010.0012.5015.0017.50421K842KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IMUXclose 8.1620-day 7.5450-day 8.93200-day 11.558.1652w high

53.2% under the 52-week high of 17.43 on 19 Aug 2026. 52-week low 5.06 on 30 Dec 2025. Last 15 sessions, 20.4% high to low

Profile

IMUX
52-week range, 25% of the way up
5.0617.43

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.

Employees92
IPOApr 17, 2014
Beta1.47
ATR, 14d0.61
Rel volume0.45
Short float15.28%
Insider own6.52%
Inst own76.25%

Snapshot

6 groups

Valuation

Index-
Market Cap111.34M
Enterprise Value-43.19M
Income-111.57M
Sales0.00M
Book/sh9.35
Cash/sh11.37
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees92
IPOApr 17, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.87
P/C0.72
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.05
Current Ratio5.05
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.81
EPS next Y-2.38
EPS next Q-0.79
EPS this Y42.01%
EPS next Y33.75%
EPS next 5Y26.88%
EPS past 3/5Y45.16% 25.99%
Sales past 3/5Y- -
EPS Y/Y TTM50.66%
Sales Y/Y TTM-
EPS Q/Q60.47%
Sales Q/Q-
EarningsAug 11 BMO
EPS/Sales Surpr.31.32% -

Ownership

Insider Own6.52%
Insider Trans0.00%
Inst Own76.25%
Inst Trans14.59%
ROA-101.15%
ROE-138.17%
ROIC-87.22%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA208.18%
SMA50-8.65%
SMA200-29.33%
Trades-

Technical

Shs Outstand13.64M
Shs Float12.76M
Short Float15.28%
Short Ratio5.77
Short Interest1.95M
52W High17.43 -53.18%
52W Low5.06 61.20%
Volatility8.03% 8.71%
ATR (14)0.61
RSI (14)51.13
Beta1.47
Rel Volume0.45
Avg Volume338.10K
Volume99,492

Performance

Perf Week2.77%
Perf Month18.43%
Perf Quarter-50.78%
Perf Half Y-36.99%
Perf YTD52.89%
Perf Year4.63%
Perf 3Y-23.02%
Perf 5Y-91.88%
Perf 10Y-99.67%
Recom1.00
Target Price43.09
Prev Close8.04
Price8.16
Change %1.49%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 23, 2026InitiatedCCantor FitzgeraldOverweight
Aug 17, 2026InitiatedWWedbushOutperform$45+451.5%
May 22, 2026InitiatedWWolfe ResearchOutperform
Apr 17, 2026InitiatedSStifelBuy$2.50-69.4%
Apr 15, 2026DowngradeDD. Boral CapitalBuy → Hold
Mar 24, 2026InitiatedGGuggenheimBuy$7-14.2%
Nov 07, 2025InitiatedRRoth CapitalBuy$3-63.2%
Sep 29, 2025InitiatedCChardan Capital MarketsBuy$13+59.3%
Mar 25, 2025InitiatedWWilliam BlairOutperform
Nov 25, 2024InitiatedHH.C. WainwrightBuy$10+22.5%

Peers

Mkt cap
TickerCompanyMkt cap
CTNMContineum Therapeutics Inc422.11M
TGTXTG Therapeutics Inc9.76B
CLNNClene Inc62.49M
BIIBBiogen Inc37.36B
RNACCartesian Therapeutics Inc213.91M
ABVXAbivax ADR8.03B
IMVTImmunovant Inc7.70B
ATRAAtara Biotherapeutics Inc83.42M
SNYSanofi ADR114.63B
NVSNovartis AG ADR292.41B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
SURISimplify Propel Opportunities ETFAUM: 74.30M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-11-0.800-1.165-0.8000.000.0010
2026Q12026-05-13-1.080-0.688-1.0810.000.008
2025Q42026-02-26-0.950-0.900-1.6030.000.008
2025Q32025-11-13-1.300-1.433-1.3190.000.009
2025Q22025-08-07-2.000-1.578-2.0290.000.006
2025Q12025-05-08-2.502-2.400-2.5140.000.007
2024Q42025-02-20-2.457-2.350-2.7930.000.006
2024Q32024-11-07-2.400-2.184-2.4060.000.016
2024Q22024-08-08-2.100-2.325-2.1110.000.004
2024Q12024-05-08-3.000-2.600-3.0410.000.005
2023Q42024-02-22-4.800-5.125-4.8330.000.004
2023Q32023-11-14-5.100-5.475-5.1080.000.004
2023Q22023-08-03-5.400-5.250-5.4010.000.004
2023Q12023-05-11-5.800-5.175-5.7880.000.004
2022Q42023-02-23-16.300-7.325-16.2830.000.004
2022Q32022-11-03-6.900-6.700-6.9440.000.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-45.200-35.000-45.2370.00-
2020FY-28.100-30.340-28.1010.000.00
2021FY-39.300-39.488-39.2960.000.00
2022FY-37.800-29.050-37.8410.000.00
2023FY-21.100-21.425-21.1220.000.00
2024FY-10.019-9.583-10.0330.000.00
2025FY-6.200-6.313-6.2000.000.00
2026FY--3.595--0.00
2027FY--2.382--0.00
2028FY--2.424--80.47
2029FY--0.633--217.29
2030FY-1.510--420.22

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-228000.000.000.00
2026Q3S2026-08-317000.000.000.00
2026Q3S2026-08-296000.000.000.00
2026Q3S2026-08-217000.000.000.00
2026Q3S2026-08-148000.000.000.00
2026Q3S2026-08-117000.000.000.00
2026Q3S2026-07-247000.000.000.00
2026Q3S2026-05-218000.000.000.00
2026Q3S2026-05-137000.000.000.00
2026Q3S2026-04-157000.000.000.00
2026Q3S2026-03-236000.000.000.00
2026Q3S2026-03-135000.000.000.00
2026Q3S2026-02-274000.000.000.00
2026Q3S2026-02-263000.000.000.00

Estimate history

EPS, annual-524-136.276-45.237-28.101-39.296-37.841-21.122-10.033-6.242-4.8059
Period201720182019202020212022202320242025TTM
EPS, quarterly-2.111-2.406-2.793-2.514-2.029-1.319-1.603-1.081-0.802
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.1060.0851.0742.1172.6343.9314.5189.01512.03813.644
Period201720182019202020212022202320242025MRQ
Shares, quarterly9.0089.0089.0159.0159.8659.86512.03813.62113.644
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.150.170.130.110.080.090.040.050.01
Gross Profit-0.15-0.17-0.13-0.11-0.08-0.09-0.04-0.05-0.01
Selling, General and Administrative Excl. Other117.73103.0697.9299.1186.4474.3348.9336.9811.98
Research and Development90.6481.9880.0583.2271.2561.1238.6422.519.60
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-117.88-103.23-98.05-99.22-86.52-74.42-48.97-37.03-12.00
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.004.800.0032.9717.250.00-3.61
Net Income Before Taxes-111.57-97.17-100.51-93.61-120.41-92.94-44.02-34.93-11.54
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-111.57-97.17-100.51-93.61-120.41-92.94-44.02-34.93-11.54
Net Income From Continuing Operations-111.57-97.17-100.51-93.61-120.41-92.94-44.02-34.93-11.54
Net Income-111.57-97.17-100.51-93.61-120.41-92.94-44.02-34.93-11.54
EPS (Recurring)-2.62-6.24-9.70-21.12-30.59-34.19-28.10-45.24-136.28
EPS (Basic, Before Extraordinaries)-4.81-6.24-10.03-21.12-37.84-39.30-28.10-45.24-136.28
EPS (Diluted)-4.81-6.24-10.03-21.12-37.84-39.30-28.10-45.24-136.28
EBITDA-117.73-103.06-97.92-99.11-86.44-74.33-48.93-36.98-11.98
Non-Operating Income (Expense)6.326.062.345.61-0.92-1.284.952.100.46
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2,885.398.868.537.107.935.952.758.560.00
Shares Outstanding13.6412.049.024.523.932.632.121.070.08
Market Capitalization109.70109.7090.1566.8942.79252.03323.66104.227.89

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.030.040.040.040.040.040.04
Gross Profit-0.03-0.03-0.04-0.04-0.04-0.04-0.04-0.04
Selling, General and Administrative Excl. Other35.2933.2023.2925.9527.0426.7825.6025.68
Research and Development25.9325.6319.0720.0121.3721.5321.6221.37
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-35.33-33.23-23.33-25.99-27.08-26.82-25.63-25.73
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-34.10-32.59-19.30-25.58-26.82-25.47-25.18-24.37
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-34.10-32.59-19.30-25.58-26.82-25.47-25.18-24.37
Net Income From Continuing Operations-34.10-32.59-19.30-25.58-26.82-25.47-25.18-24.37
Net Income-34.10-32.59-19.30-25.58-26.82-25.47-25.18-24.37
EPS (Recurring)-0.80-1.08-1.60-1.32-2.03-2.51-2.79-2.41
EPS (Basic, Before Extraordinaries)-0.80-1.08-1.60-1.32-2.03-2.51-2.79-2.41
EPS (Diluted)-0.80-1.08-1.60-1.32-2.03-2.51-2.79-2.41
EBITDA-35.29-33.20-23.29-25.95-27.04-26.78-25.60-25.68
Non-Operating Income (Expense)1.230.654.030.410.261.350.461.36
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2,876.004.471.313.611.902.041.991.91
Shares Outstanding13.6413.6212.049.879.879.029.029.01
Market Capitalization109.70151.2064.2586.9768.8198.2690.15148.63

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments15.4835.6746.67116.3786.86127.4529.3713.0756.90
Short Term Receivables4.120.650.700.300.280.290.410.190.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.263.025.169.1917.856.002.450.071.22
Total Current Assets22.8739.3352.53125.86104.99133.7532.2313.3358.12
Net Property, Plant & Equipment1.181.541.761.851.101.100.710.042.15
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.0032.9732.9732.970.00-
Other Assets0.000.000.000.040.040.040.040.000.11
Total Assets24.0540.8754.30127.75139.10167.8665.9513.3760.38
Short Term Debt Incl. Current Port. of LT Debt0.470.740.690.570.410.000.000.000.00
Accounts Payable10.147.855.104.283.753.702.421.401.05
Other Current Liabilities20.0113.5918.938.227.254.704.650.529.23
Total Current Liabilities30.6222.1824.7313.0811.408.407.071.9210.28
Long Term Debt0.110.260.640.990.580.680.5237.190.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.06
Total Liabilities30.7322.4425.3714.0711.989.087.5939.1110.34
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-6.6718.4328.93113.68127.11158.7858.36-25.7450.04
Total Shareholders Equity-6.6718.4328.93113.68127.11158.7858.36-25.7450.04
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-6.6718.4328.93113.68127.11158.7858.36-25.7450.04
Total Liabilities & Stockholders Equity24.0540.8754.30127.75139.10167.8665.9513.3760.38
Book Value Per Share-0.552.046.4028.9248.2775.0154.32-303.92472.46
Tangible Book Value Per Share-0.552.046.4028.9235.7559.4423.63-303.92472.46
Full-Time Employees929177665528261097
Price to Book Ratio0.864.891.380.391.982.041.790.644.05
Return on Assets-299.36-211.22-102.84-90.24-60.56-37.65-86.33-31.30-83.72
Return on Equity-1,653.15-424.44-131.28-100.01-65.02-40.54-98.69-94.98-96.01
Return on Invested Capital--537.67-316.58-105.00-72.78-27.60-59.33-100.79-104.06
Quick Ratio0.751.772.129.629.2115.934.566.945.65
Current Ratio0.751.772.129.629.2115.934.566.945.65

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-111.57-97.17-100.51-93.61-120.41-92.94-44.02-34.93-11.54
Depreciation0.150.170.130.110.080.090.040.050.01
Other Funds (Non Cash)16.929.3615.047.6245.6618.910.227.430.00
Funds from Operations-94.50-87.64-85.33-85.88-74.67-73.95-43.76-27.46-11.53
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital6.781.840.5615.059.53-9.28-2.37-1.361.79
Cash from Operating Activities-87.72-85.81-84.77-70.83-65.14-83.23-46.12-28.82-9.74
Capital Expenditures-0.33-0.16-0.26-0.33-0.11-0.07-0.15-0.06-0.03
Net Assets From Acquisitions0.000.000.000.000.000.000.008.150.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.002.520.00
Purchase or Sale of Investments0.000.000.009.80-9.630.000.000.000.00
Purchase of Investments0.000.000.000.00-9.630.000.000.000.00
Sale Or Maturity of Investments0.000.000.009.800.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.00-0.070.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.33-0.16-0.269.46-9.74-0.07-0.1510.54-0.03
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock254.2165.580.271.0395.7642.84144.4335.1619.26
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock254.2165.580.271.0395.7642.84144.4335.1619.26
Proceedsfrom Stock Options254.2165.580.270.9895.7542.84144.4335.1619.26
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-65.390.0074.270.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities188.8265.5874.541.0395.7642.84144.4335.1619.26
Exchange Rate Effect-0.980.20-0.520.26-0.99-0.13-0.08-0.59-0.92
Net Change in Cash99.79-20.18-11.01-60.0719.88-40.5998.0816.308.57
Free Cash Flow-88.05-85.97-85.03-71.16-65.26-83.30-46.27-28.87-9.77
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments155.10186.6315.4835.1355.3114.30
Short Term Receivables0.280.354.120.180.590.63
Inventories0.000.000.000.000.000.00
Other Current Assets2.451.783.263.963.944.04
Total Current Assets157.83188.7622.8739.2759.8418.98
Net Property, Plant & Equipment1.340.981.181.431.591.54
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets159.17189.7424.0540.7061.4320.52
Short Term Debt Incl. Current Port. of LT Debt0.240.280.470.670.770.77
Accounts Payable12.6611.0110.147.927.896.01
Other Current Liabilities18.3627.0820.0121.5018.6518.82
Total Current Liabilities31.2638.3630.6230.0827.3125.59
Long Term Debt0.330.150.110.130.200.21
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities31.5938.5130.7330.2027.5225.80
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity127.58151.23-6.6710.5033.91-5.29
Total Shareholders Equity127.58151.23-6.6710.5033.91-5.29
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity127.58151.23-6.6710.5033.91-5.29
Total Liabilities & Stockholders Equity159.17189.7424.0540.7061.4320.52
Book Value Per Share9.3511.10-0.551.063.44-0.59
Tangible Book Value Per Share9.3511.10-0.551.063.44-0.59
Full-Time Employees1009592---
Price to Book Ratio0.861.00-9.638.282.03-18.59
Return on Assets-101.15-99.20-299.36-195.41-137.69-154.64
Return on Equity-138.17-142.91-1,653.15-398.50-208.93-246.26
Return on Invested Capital-26.66-21.53--240.74-78.61-
Quick Ratio5.054.920.751.312.190.74
Current Ratio5.054.920.751.312.190.74

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-34.10-32.59-19.30-25.58-26.82-25.47
Depreciation0.030.030.040.040.040.04
Other Funds (Non Cash)6.994.621.653.661.952.10
Funds from Operations-27.07-27.94-17.61-21.88-24.82-23.34
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.9210.64-1.671.740.211.56
Cash from Operating Activities-31.00-17.30-19.28-20.14-24.61-21.78
Capital Expenditures-0.25-0.00-0.01-0.07-0.04-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.25-0.00-0.01-0.07-0.04-0.05
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.12188.640.0665.390.120.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.12188.640.0665.390.120.00
Proceedsfrom Stock Options0.12188.640.0665.390.120.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-65.3965.390.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.12188.640.060.0065.520.00
Exchange Rate Effect-0.40-0.19-0.420.030.130.46
Net Change in Cash-31.53171.15-19.65-20.1841.01-21.36
Free Cash Flow-31.25-17.30-19.29-20.21-24.64-21.82

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.28%2.0M12.8M334.35K
2026-10-1514.59%1.9M12.8M300.31K
2026-09-3016.27%2.1M12.8M249.69K
2026-09-1514.07%1.8M12.8M207.04K
2026-08-3111.69%1.5M12.8M185.62K
2026-08-1410.02%1.3M12.8M195.36K
2026-07-3110.63%1.4M13.5M212.26K
2026-07-1510.48%1.4M13.5M263.26K
2026-06-3011.77%1.6M13.5M270.17K
2026-06-1512.09%1.6M13.5M268.48K
2026-05-2913.08%1.8M13.5M302.30K
2026-05-1511.61%1.6M13.5M307.54K
2026-04-309.95%1.3M13.4M404.31K
2026-04-156.47%0.8M12.9M358.55K
2026-03-316.95%0.9M12.9M353.00K
2026-03-136.72%0.9M12.9M345.45K
2026-02-275.89%0.8M12.9M292.10K
2026-02-135.58%0.7M11.9M265.06K
2026-01-305.54%0.7M11.9M143.24K
2026-01-155.97%0.7M11.9M141.78K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.503.506.800.0012.5320.000.000.981-0.0150.001
call5.001.005.502.9410.0741.000.000.958-0.0130.001
call7.500.702.651.104.82061.000.000.666-0.0530.005
call10.000.000.450.302.02329.000.000.316-0.0520.005
call12.500.000.750.052.97374.000.000.247-0.0670.004
call15.000.000.950.473.62049.000.000.217-0.0760.004
call17.500.001.750.004.1280.000.000.200-0.0830.004
call20.000.000.950.004.5590.000.000.188-0.0880.003
call22.500.000.950.054.9891.000.000.180-0.0930.003
put2.500.000.500.004.3820.000.00-0.019-0.0140.001
put5.000.000.050.054.9630.0010.00-0.149-0.0830.003
put7.500.150.550.411.69358515.00-0.342-0.0540.005
put10.000.704.902.557.3014.000.00-0.685-0.0510.005
put12.503.506.500.006.4830.000.00-0.753-0.0660.004
put15.006.109.007.257.3060.000.00-0.783-0.0750.004
put17.508.0011.509.757.89617.000.00-0.800-0.0810.004
put20.009.5014.000.008.3270.000.00-0.812-0.0860.003
put22.5013.0015.500.006.8290.000.00-0.821-0.0900.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-02SCHEDULE 13G/ASEC
2026-10-01S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-118-KCurrent report2026-09-10SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-12S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-103Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-06SCHEDULE 13G/ASEC
2026-08-04SCHEDULE 13GSEC
2026-07-16SCHEDULE 13G/ASEC
2026-07-148-KCurrent report2026-07-14SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-05SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-05SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-05SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-05SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-05SEC
2026-07-068-KCurrent report2026-06-29SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Aberdeen Group plc7.99%
BVF INC/IL5.62%
MILLENNIUM MANAGEMENT LLC5.44%
Avidity Partners Management LP4.92%
BRAIDWELL LP4.74%
Laurion Capital Management LP4.47%
VANGUARD CAPITAL MANAGEMENT LLC4.20%
Jones Hill Capital LP3.96%
Nantahala Capital Management, LLC3.68%
Woodline Partners LP3.46%

Funds

Fund% owned
abrdn Healthcare Investors3.48%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.93%
abrdn Life Sciences Investors2.22%
VANGUARD EXTENDED MARKET INDEX FUND1.17%
Fidelity Extended Market Index Fund0.51%
abrdn World Healthcare Fund0.35%
iShares Micro-Cap ETF0.34%
Simplify Propel Opportunities ETF0.23%
Fidelity Total Market Index Fund0.21%
Fidelity Series Total Market Index Fund0.16%

OakChart. IMUX. Cached 15 minutes.

Some panels did not load: insider.